| DB ID | MyCo_1582 |
| Title | Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis |
| Year | 2003 |
| PMID | 12716367 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | Haemato-oncological patients with neutropenia |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study concerned the routine development of new methodologies in the laboratory and did not involve investigational drugs or additional sampling. Therefore, the study was considered by the ethics committee to be a quality-control investigation of the hospital and not experimentation with human beings that would require formal ethics review and informed consent. However, all patients signed a declaration that they allowed their clinical data and specimens to be used for research. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Netherlands |
| Cohort | The study consisted of two parts. First, between February 1999 and April 2000, we performed a prospective, blinded study. Thereafter, between June 2000 and October 2001, a prospective, non-blinded study was carried out. Both studies included haemato-oncological patients that had an expected neutropenia (less than 0.5 x109 cells/l) for at least 10 d and were aged at least 18 years. |
| Cohort No. | 160 |
| Age Group | >18 |
| P Value | None |
| Sensitivity | 0.47 |
| Specificity | 0.93 |
| Positive Predictive Value | 0.73 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) remains a major challenge in the management of immunocompromised patients. In neutropenic patients, mortality rates range from 50% to 90% in different settings. This is probably due to the difficulty in obtaining a reliable diagnosis at an early stage and the relatively poor efficacy of the currently available antifungal armamentarium. The gold standard for the diagnosis of IPA is the histological demonstration of the fungus in a lung biopsy with concomitant fungal growth from the same specimen. However, biopsies are often precluded by thrombocytopenia or by the critical condition of the patient. Therefore, the diagnosis of IPA before death is mostly based on clinical signs, computerized tomography (CT) scan findings and culture of respiratory specimens. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Sandwich ELISA Kit (Platelia Aspergillus, Sanofi Diagnostics Pasteur, Belgium) |
| Assay Data | None |
| Validation Techniques used | ELISA, CT |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
